{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T18:26:56Z","timestamp":1793557616632,"version":"4.5.0"},"reference-count":196,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82400753"],"award-info":[{"award-number":["82400753"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the National Funded Postdoctoral Researchers Program","award":["GZC20230641"],"award-info":[{"award-number":["GZC20230641"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2024MD753935"],"award-info":[{"award-number":["2024MD753935"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Heilongjiang Postdoctoral Financial Assistance","award":["LBH-Z23219"],"award-info":[{"award-number":["LBH-Z23219"]}]},{"name":"Haiyan Foundation of Harbin Medical University Cancer Hospital","award":["JJZD2024-08"],"award-info":[{"award-number":["JJZD2024-08"]}]},{"DOI":"10.13039\/501100005046","name":"Natural Science Foundation of Heilongjiang Province","doi-asserted-by":"publisher","award":["PL2024H158"],"award-info":[{"award-number":["PL2024H158"]}],"id":[{"id":"10.13039\/501100005046","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Heilongjiang Provincial Institution of Higher Learning Basic Research Funds Basic Research Project","award":["2023-KYYWF-0201"],"award-info":[{"award-number":["2023-KYYWF-0201"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pancreatic cancer (PC) is among the deadliest types of cancer, with very low chances of survival. It is often asymptomatic in the early stage, making diagnosis difficult. Therefore, it is typically found at an advanced stage, resulting in patients missing the opportunity for radical surgery. The complex biological characteristics of PC, coupled with the difficulties in drug delivery and tumor resistance, limit the effectiveness of drug therapy. Due to their compatibility with biological systems and low likelihood of triggering an immune response, exosomes are seen as a promising method for drug delivery. They are capable of targeting and penetrating tissues inside the body and can be engineered through surface modification and drug loading. Engineered exosomes possess controllable and diverse drug-carrying capabilities, which can enhance drug internalization and cellular uptake. Owing to their special properties and the potential to overcome the drawbacks of standard therapies, engineered exosomes have appeared as a promising treatment option. This review aims to comprehensively summarize the current application status and progress of engineered exosomes used in PC therapy.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1186\/s12951-025-03697-0","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T14:52:40Z","timestamp":1759157560000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Engineered exosomes: a promising approach for overcoming challenges in pancreatic cancer therapy"],"prefix":"10.1186","volume":"23","author":[{"given":"Mo","family":"Sha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"10485","key":"3697_CR1","first-page":"1182","volume":"405","author":"TF Stoop","year":"2025","unstructured":"Stoop TF, Javed AA, Oba A, Koerkamp BG, Seufferlein T, Wilmink JW, et al. Pancreat Cancer Lancet. 2025;405(10485):1182\u2013202.","journal-title":"Pancreat Cancer Lancet"},{"key":"3697_CR2","doi-asserted-by":"publisher","unstructured":"Hu ZI, O'Reilly EM. Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2024 ;21(1):7-24. https:\/\/doi.org\/10.1038\/s41575-023-00840-w","DOI":"10.1038\/s41575-023-00840-w"},{"key":"3697_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.06.027","author":"J Cai","year":"2021","unstructured":"Cai J, Chen H, Lu M, Zhang Y, Lu B, You L, Zhang T, Dai M, Zhao Y. Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis. Cancer Lett. 2021;520:1-11. https:\/\/doi.org\/10.1016\/j.canlet.2021.06.027","journal-title":"Cancer Lett"},{"issue":"3","key":"3697_CR4","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ejso.2006.10.004","volume":"33","author":"KS Goonetilleke","year":"2007","unstructured":"Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19\u20139) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33(3):266\u201370.","journal-title":"Eur J Surg Oncol"},{"issue":"9791","key":"3697_CR5","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","volume":"378","author":"A Vincent","year":"2011","unstructured":"Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378(9791):607\u201320.","journal-title":"Lancet"},{"key":"3697_CR6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.03.056","author":"LD Wood","year":"2022","unstructured":"Wood LD, Canto MI, Jaffee EM, Simeone DM. Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment. Gastroenterology. 2022 ;163(2):386-402. https:\/\/doi.org\/10.1053\/j.gastro.2022.03.056","journal-title":"Gastroenterology"},{"issue":"9","key":"3697_CR7","first-page":"851","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM. Pancreat Cancer: Rev JAMA. 2021;326(9):851\u201362.","journal-title":"Pancreat Cancer: Rev JAMA"},{"issue":"1","key":"3697_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-024-01561-6","volume":"17","author":"P Farhangnia","year":"2024","unstructured":"Farhangnia P, Khorramdelazad H, Nickho H, Delbandi A-A. Current and future immunotherapeutic approaches in pancreatic cancer treatment. J Hematol Oncol. 2024;17(1):40.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"3697_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5152\/tjg.2024.24544","volume":"36","author":"P Wenzel","year":"2024","unstructured":"Wenzel P, Mogler C, G\u00f6rg\u00fcl\u00fc K, Alg\u00fcl H. Pancreatic cancer: current concepts, trends, and future directions. Turk J Gastroenterol. 2024;36(2):69\u201381.","journal-title":"Turk J Gastroenterol"},{"issue":"9","key":"3697_CR10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","volume":"17","author":"WJ Ho","year":"2020","unstructured":"Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nat Rev Clin Oncol. 2020;17(9):527\u201340.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"3697_CR11","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, Maitra A. Pancreatic cancer: advances and challenges. Cell. 2023;186(8):1729\u201354.","journal-title":"Cell"},{"key":"3697_CR12","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.semcancer.2021.05.030","volume":"76","author":"B Traub","year":"2021","unstructured":"Traub B, Link K-H, Kornmann M. Curing pancreatic cancer. Semin Cancer Biol. 2021;76:232\u201346.","journal-title":"Semin Cancer Biol"},{"issue":"34","key":"3697_CR13","doi-asserted-by":"publisher","first-page":"7591","DOI":"10.1039\/D0TB01499K","volume":"8","author":"H Peng","year":"2020","unstructured":"Peng H, Ji W, Zhao R, Yang J, Lu Z, Li Y, et al. Exosome: a significant nano-scale drug delivery carrier. J Mater Chem B. 2020;8(34):7591\u2013608.","journal-title":"J Mater Chem B"},{"key":"3697_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13578-019-0282-2","volume":"9","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Liu Y, Liu H, Tang WH. Exosomes: biogenesis, biologic function and clinical potential. Cell Biosci. 2019;9:19.","journal-title":"Cell Biosci"},{"issue":"1","key":"3697_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01382-y","volume":"8","author":"M Zhang","year":"2023","unstructured":"Zhang M, Hu S, Liu L, Dang P, Liu Y, Sun Z, et al. Engineered exosomes from different sources for cancer-targeted therapy. Signal Transduct Target Ther. 2023;8(1):124.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"3697_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00840-w","volume":"8","author":"LM Doyle","year":"2019","unstructured":"Doyle LM, Wang MZ. Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. Cells. 2019;8(7):727. https:\/\/doi.org\/10.1038\/s41575-023-00840-w","journal-title":"Cells"},{"key":"3697_CR17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jconrel.2023.03.013","volume":"356","author":"A Joorabloo","year":"2023","unstructured":"Joorabloo A, Liu T. Engineering exosome-based biomimetic nanovehicles for wound healing. J Control Release. 2023;356:463\u201380.","journal-title":"J Control Release"},{"issue":"9","key":"3697_CR18","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.cmet.2021.08.006","volume":"33","author":"R Isaac","year":"2021","unstructured":"Isaac R, Reis FCG, Ying W, Olefsky JM. Exosomes as mediators of intercellular crosstalk in metabolism. Cell Metab. 2021;33(9):1744\u201362.","journal-title":"Cell Metab"},{"issue":"1","key":"3697_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12964-021-00730-1","volume":"19","author":"S Gurung","year":"2021","unstructured":"Gurung S, Perocheau D, Touramanidou L, Baruteau J. The exosome journey: from biogenesis to uptake and intracellular signalling. Cell Commun Signal. 2021;19(1):47.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"3697_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13010122","volume":"13","author":"RO Elliott","year":"2021","unstructured":"Elliott RO, He M. Unlocking the power of exosomes for crossing biological barriers in drug delivery. Pharmaceutics. 2021;13(1):122. https:\/\/doi.org\/10.3390\/pharmaceutics13010122","journal-title":"Pharmaceutics"},{"key":"3697_CR21","doi-asserted-by":"crossref","unstructured":"Araldi RP, D\u2019Amelio F, Vigerelli H, de Melo TC, Kerkis I. Stem Cell-Derived exosomes as therapeutic approach for neurodegenerative disorders: from biology to biotechnology. Cells. 2020;9(12):2663.","DOI":"10.3390\/cells9122663"},{"key":"3697_CR22","doi-asserted-by":"publisher","first-page":"9355","DOI":"10.2147\/IJN.S281890","volume":"15","author":"J Shao","year":"2020","unstructured":"Shao J, Zaro J, Shen Y. Advances in exosome-based drug delivery and tumor targeting: from tissue distribution to intracellular fate. Int J Nanomed. 2020;15:9355\u201371.","journal-title":"Int J Nanomed"},{"key":"3697_CR23","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.actbio.2023.09.023","volume":"171","author":"S Deng","year":"2023","unstructured":"Deng S, Cao H, Cui X, Fan Y, Wang Q, Zhang X. Optimization of exosome-based cell-free strategies to enhance endogenous cell functions in tissue regeneration. Acta Biomater. 2023;171:68\u201384.","journal-title":"Acta Biomater"},{"issue":"7","key":"3697_CR24","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.7150\/thno.52570","volume":"11","author":"Y Liang","year":"2021","unstructured":"Liang Y, Duan L, Lu J, Xia J. Engineering exosomes for targeted drug delivery. Theranostics. 2021;11(7):3183\u201395.","journal-title":"Theranostics"},{"issue":"22","key":"3697_CR25","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.1113\/JP282799","volume":"601","author":"F Malekian","year":"2023","unstructured":"Malekian F, Shamsian A, Kodam SP, Ullah M. Exosome engineering for efficient and targeted drug delivery: current status and future perspective. J Physiol. 2023;601(22):4853\u201372.","journal-title":"J Physiol"},{"key":"3697_CR26","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.jconrel.2020.10.020","volume":"329","author":"J Wang","year":"2021","unstructured":"Wang J, Chen D, Ho EA. Challenges in the development and establishment of exosome-based drug delivery systems. J Control Release. 2021;329:894\u2013906.","journal-title":"J Control Release"},{"issue":"1","key":"3697_CR27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-022-01305-4","volume":"15","author":"MDA Paskeh","year":"2022","unstructured":"Paskeh MDA, Entezari M, Mirzaei S, Zabolian A, Saleki H, Naghdi MJ, et al. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. J Hematol Oncol. 2022;15(1):83.","journal-title":"J Hematol Oncol"},{"key":"3697_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.09.022","author":"BT Gr\u00fcnwald","year":"2021","unstructured":"Gr\u00fcnwald BT, Devisme A, Andrieux G, Vyas F, Aliar K, McCloskey CW, et al. Spatially confined sub-tumor microenvironments in pancreatic cancer. Cell. 2021;184(22):5577-5592.e18 . https:\/\/doi.org\/10.1016\/j.cell.2021.09.022","journal-title":"Cell"},{"issue":"3","key":"3697_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41568-021-00418-1","volume":"22","author":"AA Connor","year":"2022","unstructured":"Connor AA, Gallinger S. Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data. Nat Rev Cancer. 2022;22(3):131\u201342.","journal-title":"Nat Rev Cancer"},{"key":"3697_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040799","author":"C Leroux","year":"2021","unstructured":"Leroux C, Konstantinidou G. Targeted therapies for pancreatic cancer: overview of current treatments and new opportunities for personalized oncology. Cancers. 2021;13(4):799. https:\/\/doi.org\/10.3390\/cancers13040799","journal-title":"Cancers"},{"key":"3697_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.03.015","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, Zhou Z, Du X, Lin X, Liang Z-M, Chen S, et al. Cancer cell-derived arginine fuels polyamine biosynthesis in tumor-associated macrophages to promote immune evasion. Cancer Cell. 2025;43(6):1045-1060.e7. https:\/\/doi.org\/10.1016\/j.ccell.2025.03.015","journal-title":"Cancer Cell"},{"key":"3697_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/science.adn8608","volume-title":"Platelet factor 4-induced TH1-Treg polarization suppresses antitumor immunity","author":"A Kuratani","year":"2024","unstructured":"Kuratani A, Okamoto M, Kishida K, Okuzaki D, Sasai M, Sakaguchi S, et al. Platelet factor 4-induced TH1-Treg polarization suppresses antitumor immunity. Science. 2024;386:eadn8608. https:\/\/doi.org\/10.1126\/science.adn8608"},{"issue":"11","key":"3697_CR33","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1158\/2159-8290.CD-21-1714","volume":"12","author":"JA Grout","year":"2022","unstructured":"Grout JA, Sirven P, Leader AM, Maskey S, Hector E, Puisieux I, et al. Spatial positioning and matrix programs of Cancer-Associated fibroblasts promote T-cell exclusion in human lung tumors. Cancer Discov. 2022;12(11):2606\u201325.","journal-title":"Cancer Discov"},{"issue":"1","key":"3697_CR34","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-024-01600-2","volume":"17","author":"F Zhang","year":"2024","unstructured":"Zhang F, Ma Y, Li D, Wei J, Chen K, Zhang E, et al. Cancer associated fibroblasts and metabolic reprogramming: unraveling the intricate crosstalk in tumor evolution. J Hematol Oncol. 2024;17(1):80.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"3697_CR35","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ccell.2022.04.011","volume":"40","author":"H Huang","year":"2022","unstructured":"Huang H, Wang Z, Zhang Y, Pradhan RN, Ganguly D, Chandra R, et al. Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Cancer Cell. 2022;40(6):656-673.e7.","journal-title":"Cancer Cell"},{"issue":"6","key":"3697_CR36","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.tips.2022.03.005","volume":"43","author":"X Huang","year":"2022","unstructured":"Huang X, Zhang G, Liang T. Subtyping for pancreatic cancer precision therapy. Trends Pharmacol Sci. 2022;43(6):482\u201394.","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"3697_CR37","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s43018-023-00526-x","volume":"4","author":"S B\u00e4rthel","year":"2023","unstructured":"B\u00e4rthel S, Falcomat\u00e0 C, Rad R, Theis FJ, Saur D. Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy. Nat Cancer. 2023;4(4):454\u201367.","journal-title":"Nat Cancer"},{"key":"3697_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133293","author":"Y Masugi","year":"2022","unstructured":"Masugi Y. The desmoplastic stroma of pancreatic cancer: multilayered levels of heterogeneity, clinical significance, and therapeutic opportunities. Cancers. 2022;14(13):3293. https:\/\/doi.org\/10.3390\/cancers14133293","journal-title":"Cancers"},{"key":"3697_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116492","volume":"229","author":"M Espona-Fiedler","year":"2024","unstructured":"Espona-Fiedler M, Patthey C, Lindblad S, Sarr\u00f3 I, \u00d6hlund D. Overcoming therapy resistance in pancreatic cancer: new insights and future directions. Biochem Pharmacol. 2024;229:116492.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"3697_CR40","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccell.2023.01.001","volume":"41","author":"X Liu","year":"2023","unstructured":"Liu X, Song J, Zhang H, Liu X, Zuo F, Zhao Y, et al. Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell. 2023;41(2):272-287.e9.","journal-title":"Cancer Cell"},{"issue":"1","key":"3697_CR41","doi-asserted-by":"publisher","first-page":"7041","DOI":"10.1038\/s41467-021-27349-7","volume":"12","author":"Y Deng","year":"2021","unstructured":"Deng Y, Xia X, Zhao Y, Zhao Z, Martinez C, Yin W, et al. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. Nat Commun. 2021;12(1):7041.","journal-title":"Nat Commun"},{"issue":"4","key":"3697_CR42","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1152\/physrev.00042.2019","volume":"100","author":"E Hessmann","year":"2020","unstructured":"Hessmann E, Buchholz SM, Demir IE, Singh SK, Gress TM, Ellenrieder V, et al. Microenvironmental determinants of pancreatic cancer. Physiol Rev. 2020;100(4):1707\u201351.","journal-title":"Physiol Rev"},{"issue":"1","key":"3697_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00544-0","volume":"6","author":"J Huang","year":"2021","unstructured":"Huang J, Zhang L, Wan D, Zhou L, Zheng S, Lin S, et al. Extracellular matrix and its therapeutic potential for cancer treatment. Signal Transduct Target Ther. 2021;6(1):153.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"3697_CR44","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41568-024-00740-4","volume":"24","author":"L Arpinati","year":"2024","unstructured":"Arpinati L, Carradori G, Scherz-Shouval R. CAF-induced physical constraints controlling T cell state and localization in solid tumours. Nat Rev Cancer. 2024;24(10):676\u201393.","journal-title":"Nat Rev Cancer"},{"key":"3697_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/biom11060901","author":"RS Ahmad","year":"2021","unstructured":"Ahmad RS, Eubank TD, Lukomski S, Boone BA. Immune cell modulation of the extracellular matrix contributes to the pathogenesis of pancreatic cancer. Biomolecules. 2021;11(6):901. https:\/\/doi.org\/10.3390\/biom11060901","journal-title":"Biomolecules"},{"issue":"11","key":"3697_CR46","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.2174\/0115680096284588240105051402","volume":"24","author":"C Grobbelaar","year":"2024","unstructured":"Grobbelaar C, Kgomo M, Mabeta P. Angiogenesis and pancreatic cancer: novel approaches to overcome treatment resistance. Curr Cancer Drug Targets. 2024;24(11):1116\u201327.","journal-title":"Curr Cancer Drug Targets"},{"key":"3697_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174442","author":"B Ferrara","year":"2021","unstructured":"Ferrara B, Pignatelli C, Cossutta M, Citro A, Courty J, Piemonti L. The extracellular matrix in pancreatic cancer: description of a complex network and promising therapeutic options. Cancers (Basel). 2021;13(17):4442. https:\/\/doi.org\/10.3390\/cancers13174442","journal-title":"Cancers (Basel)"},{"issue":"8","key":"3697_CR48","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","volume":"17","author":"AN Hosein","year":"2020","unstructured":"Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020;17(8):487\u2013505.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"3697_CR49","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.2337\/db19-1034","volume":"69","author":"MP Dybala","year":"2020","unstructured":"Dybala MP, Kuznetsov A, Motobu M, Hendren-Santiago BK, Philipson LH, Chervonsky AV, et al. Integrated pancreatic blood flow: bidirectional microcirculation between endocrine and exocrine pancreas. Diabetes. 2020;69(7):1439\u201350.","journal-title":"Diabetes"},{"issue":"10","key":"3697_CR50","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1007\/s00125-020-05203-7","volume":"63","author":"MA Atkinson","year":"2020","unstructured":"Atkinson MA, Campbell-Thompson M, Kusmartseva I, Kaestner KH. Organisation of the human pancreas in health and in diabetes. Diabetologia. 2020;63(10):1966\u201373.","journal-title":"Diabetologia"},{"issue":"4","key":"3697_CR51","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/17512433.2024.2319340","volume":"17","author":"B Toledo","year":"2024","unstructured":"Toledo B, Deiana C, Scian\u00f2 F, Brandi G, Marchal JA, Per\u00e1n M, et al. Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives. Expert Rev Clin Pharmacol. 2024;17(4):323\u201347.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"3697_CR52","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41420-024-01920-9","volume":"10","author":"V Kumar","year":"2024","unstructured":"Kumar V, Sethi B, Staller DW, Shrestha P, Mahato RI. Gemcitabine elaidate and ONC201 combination therapy for inhibiting pancreatic cancer in a KRAS mutated syngeneic mouse model. Cell Death Discov. 2024;10(1):158.","journal-title":"Cell Death Discov"},{"key":"3697_CR53","doi-asserted-by":"publisher","DOI":"10.1172\/JCI153470","author":"H Hu","year":"2023","unstructured":"Hu H, Cheng R, Wang Y, Wang X, Wu J, Kong Y, et al. Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47. J Clin Invest. 2023;133(2):e153470. https:\/\/doi.org\/10.1172\/JCI153470","journal-title":"J Clin Invest"},{"issue":"10","key":"3697_CR54","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1158\/1535-7163.MCT-12-0562","volume":"11","author":"F Liu","year":"2012","unstructured":"Liu F, Korc M. Cdk4\/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther. 2012;11(10):2138\u201348.","journal-title":"Mol Cancer Ther"},{"issue":"13\u201314","key":"3697_CR55","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1101\/gad.348523.121","volume":"35","author":"GL Beatty","year":"2021","unstructured":"Beatty GL, Werba G, Lyssiotis CA, Simeone DM. The biological underpinnings of therapeutic resistance in pancreatic cancer. Genes Dev. 2021;35(13\u201314):940\u201362.","journal-title":"Genes Dev"},{"issue":"6","key":"3697_CR56","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s11684-023-1050-6","volume":"17","author":"Z Jiang","year":"2023","unstructured":"Jiang Z, Zheng X, Li M, Liu M. Improving the prognosis of pancreatic cancer: insights from epidemiology, genomic alterations, and therapeutic challenges. Front Med. 2023;17(6):1135\u201369.","journal-title":"Front Med"},{"issue":"12","key":"3697_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202412574","volume":"12","author":"L Zhang","year":"2025","unstructured":"Zhang L, Ma J, Zhang J, Hu M, Cheng J, Hu B, et al. Radiotherapy-associated cellular senescence and EMT alterations contribute to distinct disease relapse patterns in locally advanced cervical cancer. Adv Sci. 2025;12(12):e2412574.","journal-title":"Adv Sci"},{"key":"3697_CR58","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1146\/annurev-pathmechdis-051222-122423","volume":"19","author":"R Fontana","year":"2024","unstructured":"Fontana R, Mestre-Farrera A, Yang J. Update on Epithelial-Mesenchymal plasticity in cancer progression. Annu Rev Pathol. 2024;19:133\u201356.","journal-title":"Annu Rev Pathol"},{"key":"3697_CR59","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20200401","author":"J Du","year":"2020","unstructured":"Du J, Gu J, Li J. Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels. Biosci Rep. 2020;40(7):BSR20200401. https:\/\/doi.org\/10.1042\/BSR20200401","journal-title":"Biosci Rep"},{"issue":"1","key":"3697_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-023-00528-z","volume":"23","author":"P Yang","year":"2023","unstructured":"Yang P, Mao K, Gao Y, Wang Z, Wang J, Chen Y, et al. Tumor size measurements of pancreatic cancer with neoadjuvant therapy based on RECIST guidelines: is MRI as effective as CT? Cancer Imaging. 2023;23(1):8.","journal-title":"Cancer Imaging"},{"issue":"5","key":"3697_CR61","doi-asserted-by":"publisher","DOI":"10.1148\/rg.230047","volume":"44","author":"F Castagnoli","year":"2024","unstructured":"Castagnoli F, Mencel J, Ap Dafydd D, Gough J, Drake B, McAddy NC, et al. Response evaluation criteria in gastrointestinal and abdominal cancers: which to use and how to measure. Radiographics. 2024;44(5):e230047.","journal-title":"Radiographics"},{"issue":"36","key":"3697_CR62","doi-asserted-by":"publisher","first-page":"5135","DOI":"10.2217\/fon-2021-0533","volume":"17","author":"M Karunakaran","year":"2021","unstructured":"Karunakaran M, Barreto SG. Surgery for pancreatic cancer: current controversies and challenges. Future Oncol (London England). 2021;17(36):5135\u201362.","journal-title":"Future Oncol (London England)"},{"issue":"10","key":"3697_CR63","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00595-020-02028-0","volume":"50","author":"RJ Torphy","year":"2020","unstructured":"Torphy RJ, Fujiwara Y, Schulick RD. Pancreatic cancer treatment: better, but a long way to go. Surg Today. 2020;50(10):1117\u201325.","journal-title":"Surg Today"},{"issue":"4","key":"3697_CR64","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.hbpd.2021.12.006","volume":"21","author":"C de la Pinta","year":"2022","unstructured":"de la Pinta C. Radiomics in pancreatic cancer for oncologist: present and future. Hepatobiliary Pancreat Dis Int. 2022;21(4):356\u201361.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"12","key":"3697_CR65","first-page":"908","volume":"63","author":"S Sirtl","year":"2023","unstructured":"Sirtl S, Vornh\u00fclz M, Hofmann FO, Mayerle J, Beyer G. Pancreatic cancer-screening or surveillance? Radiol (Heidelb). 2023;63(12):908\u201315.","journal-title":"Radiol (Heidelb)"},{"key":"3697_CR66","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1146\/annurev-biochem-013118-111902","volume":"88","author":"DM Pegtel","year":"2019","unstructured":"Pegtel DM, Gould SJ. Exosomes. Annu Rev Biochem. 2019;88:487\u2013514.","journal-title":"Annu Rev Biochem"},{"issue":"10","key":"3697_CR67","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1007\/s13346-021-01087-1","volume":"12","author":"J He","year":"2022","unstructured":"He J, Ren W, Wang W, Han W, Jiang L, Zhang D, et al. Exosomal targeting and its potential clinical application. Drug Deliv Transl Res. 2022;12(10):2385\u2013402.","journal-title":"Drug Deliv Transl Res"},{"issue":"1","key":"3697_CR68","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13287-023-03345-0","volume":"14","author":"C Zhou","year":"2023","unstructured":"Zhou C, Zhang B, Yang Y, Jiang Q, Li T, Gong J, et al. Stem cell-derived exosomes: emerging therapeutic opportunities for wound healing. Stem Cell Res Ther. 2023;14(1):107.","journal-title":"Stem Cell Res Ther"},{"key":"3697_CR69","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jare.2021.01.001","volume":"31","author":"N Parada","year":"2021","unstructured":"Parada N, Romero-Trujillo A, Georges N, Alcayaga-Miranda F. Camouflage strategies for therapeutic exosomes evasion from phagocytosis. J Adv Res. 2021;31:61\u201374.","journal-title":"J Adv Res"},{"issue":"Pt A","key":"3697_CR70","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.addr.2016.02.006","volume":"106","author":"P Vader","year":"2016","unstructured":"Vader P, Mol EA, Pasterkamp G, Schiffelers RM. Extracellular vesicles for drug delivery. Adv Drug Deliv Rev. 2016;106(Pt A):148\u201356.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"3697_CR71","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12964-025-02268-y","volume":"23","author":"SG Gabaran","year":"2025","unstructured":"Gabaran SG, Ghasemzadeh N, Rahnama M, Karatas E, Akbari A, Rezaie J. Functionalized exosomes for targeted therapy in cancer and regenerative medicine: genetic, chemical, and physical modifications. Cell Commun Signal. 2025;23(1):265.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"3697_CR72","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12951-024-02298-7","volume":"22","author":"Q Yang","year":"2024","unstructured":"Yang Q, Li S, Ou H, Zhang Y, Zhu G, Li S, et al. Exosome-based delivery strategies for tumor therapy: an update on modification, loading, and clinical application. J Nanobiotechnol. 2024;22(1):41.","journal-title":"J Nanobiotechnol"},{"issue":"6","key":"3697_CR73","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s40259-024-00684-z","volume":"38","author":"CS Lee","year":"2024","unstructured":"Lee CS, Kulkarni Y, Pierre V, Maski M, Wanner C. Adverse impacts of pegylated protein therapeutics: a targeted literature review. BioDrugs. 2024;38(6):795\u2013819.","journal-title":"BioDrugs"},{"issue":"Pt B","key":"3697_CR74","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jconrel.2016.06.040","volume":"244","author":"P Zhang","year":"2016","unstructured":"Zhang P, Sun F, Liu S, Jiang S. Anti-PEG antibodies in the clinic: current issues and beyond pegylation. J Control Release. 2016;244(Pt B):184\u201393.","journal-title":"J Control Release"},{"key":"3697_CR75","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jconrel.2020.07.042","volume":"326","author":"S Salunkhe","year":"2020","unstructured":"Salunkhe S, Dheeraj, Basak M, Chitkara D, Mittal A. Surface functionalization of exosomes for target-specific delivery and in vivo imaging & tracking: strategies and significance. J Control Release. 2020;326:599\u2013614.","journal-title":"J Control Release"},{"key":"3697_CR76","doi-asserted-by":"publisher","first-page":"7137","DOI":"10.2147\/IJN.S464249","volume":"19","author":"M Bahadorani","year":"2024","unstructured":"Bahadorani M, Nasiri M, Dellinger K, Aravamudhan S, Zadegan R. Engineering exosomes for therapeutic applications: decoding biogenesis, content modification, and cargo loading strategies. Int J Nanomed. 2024;19:7137\u201364.","journal-title":"Int J Nanomed"},{"issue":"4","key":"3697_CR77","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s12276-024-01209-y","volume":"56","author":"YJ Lee","year":"2024","unstructured":"Lee YJ, Shin KJ, Chae YC. Regulation of cargo selection in exosome biogenesis and its biomedical applications in cancer. Exp Mol Med. 2024;56(4):877\u201389.","journal-title":"Exp Mol Med"},{"key":"3697_CR78","doi-asserted-by":"publisher","first-page":"7923","DOI":"10.2147\/IJN.S444582","volume":"18","author":"J Tian","year":"2023","unstructured":"Tian J, Han Z, Song D, Peng Y, Xiong M, Chen Z, et al. Engineered exosome for drug delivery: recent development and clinical applications. Int J Nanomed. 2023;18:7923\u201340.","journal-title":"Int J Nanomed"},{"key":"3697_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/cells12101416","author":"H Zeng","year":"2023","unstructured":"Zeng H, Guo S, Ren X, Wu Z, Liu S, Yao X. Current strategies for exosome cargo loading and targeting delivery. Cells. 2023;12(10):1416. https:\/\/doi.org\/10.3390\/cells12101416","journal-title":"Cells"},{"issue":"14","key":"3697_CR80","doi-asserted-by":"publisher","first-page":"e2005709","DOI":"10.1002\/adma.202005709","volume":"33","author":"X Zhang","year":"2021","unstructured":"Zhang X, Zhang H, Gu J, Zhang J, Shi H, Qian H, et al. Engineered extracellular vesicles for cancer therapy. Adv Mater. 2021;33(14):e2005709.","journal-title":"Adv Mater"},{"issue":"5","key":"3697_CR81","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s11095-017-2123-5","volume":"34","author":"DS Sutaria","year":"2017","unstructured":"Sutaria DS, Badawi M, Phelps MA, Schmittgen TD. Achieving the promise of therapeutic extracellular vesicles: the devil is in details of therapeutic loading. Pharm Res. 2017;34(5):1053\u201366.","journal-title":"Pharm Res"},{"issue":"2","key":"3697_CR82","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s13346-022-01225-3","volume":"13","author":"M Dimik","year":"2023","unstructured":"Dimik M, Abeysinghe P, Logan J, Mitchell M. The exosome: a review of current therapeutic roles and capabilities in human reproduction. Drug Deliv Transl Res. 2023;13(2):473\u2013502.","journal-title":"Drug Deliv Transl Res"},{"key":"3697_CR83","first-page":"126","volume":"36","author":"S Moghassemi","year":"2024","unstructured":"Moghassemi S, Dadashzadeh A, Sousa MJ, Vlieghe H, Yang J, Le\u00f3n-F\u00e9lix CM, et al. Extracellular vesicles in nanomedicine and regenerative medicine: A review over the last decade. Bioact Mater. 2024;36:126\u201356.","journal-title":"Bioact Mater"},{"key":"3697_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/biology12091178","author":"P Kumar","year":"2023","unstructured":"Kumar P, Mehta D, Bissler JJ. Physiologically based pharmacokinetic modeling of extracellular vesicles. Biology (Basel). 2023;12(9):1178. https:\/\/doi.org\/10.3390\/biology12091178","journal-title":"Biology (Basel)"},{"issue":"1","key":"3697_CR85","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12943-025-02372-0","volume":"24","author":"JJJ Liu","year":"2025","unstructured":"Liu JJJ, Liu D, To SKY, Wong AST. Exosomes in cancer nanomedicine: biotechnological advancements and innovations. Mol Cancer. 2025;24(1):166.","journal-title":"Mol Cancer"},{"issue":"1","key":"3697_CR86","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12951-024-02452-1","volume":"22","author":"X Xue","year":"2024","unstructured":"Xue X, Wang X, Pang M, Yu L, Qian J, Li X, et al. An exosomal strategy for targeting cancer-associated fibroblasts mediated tumors desmoplastic microenvironments. J Nanobiotechnol. 2024;22(1):196.","journal-title":"J Nanobiotechnol"},{"issue":"10","key":"3697_CR87","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7287","volume":"13","author":"AC Larson","year":"2024","unstructured":"Larson AC, Doty KR, Solheim JC. The double life of a chemotherapy drug: immunomodulatory functions of gemcitabine in cancer. Cancer Med. 2024;13(10):e7287.","journal-title":"Cancer Med"},{"issue":"1","key":"3697_CR88","first-page":"35","volume":"17","author":"H Han","year":"2022","unstructured":"Han H, Li S, Zhong Y, Huang Y, Wang K, Jin Q, et al. Emerging pro-drug and nano-drug strategies for gemcitabine-based cancer therapy. Asian J Pharm Sci. 2022;17(1):35\u201352.","journal-title":"Asian J Pharm Sci"},{"issue":"4","key":"3697_CR89","volume":"4","author":"O Abdel-Rahman","year":"2018","unstructured":"Abdel-Rahman O, Elsayed Z, Elhalawani H. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. Cochrane Database Syst Rev. 2018;4(4):CD011746.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"3697_CR90","doi-asserted-by":"publisher","first-page":"C540","DOI":"10.1152\/ajpcell.00331.2022","volume":"324","author":"AK Beutel","year":"2023","unstructured":"Beutel AK, Halbrook CJ. Barriers and opportunities for gemcitabine in pancreatic cancer therapy. Am J Physiol Cell Physiol. 2023;324(2):C540\u201352.","journal-title":"Am J Physiol Cell Physiol"},{"key":"3697_CR91","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jconrel.2024.02.037","volume":"368","author":"JF Creeden","year":"2024","unstructured":"Creeden JF, Sevier J, Zhang J-T, Lapitsky Y, Brunicardi FC, Jin G, et al. Smart exosomes enhance PDAC targeted therapy. J Control Release. 2024;368:413\u201329.","journal-title":"J Control Release"},{"key":"3697_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13091493","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Zheng Y, Zhu Y, Zhang Y, Zhu H, Liu T. M1 macrophage-derived exosomes loaded with gemcitabine and deferasirox against chemoresistant pancreatic cancer. Pharmaceutics. 2021;13(9):1493. https:\/\/doi.org\/10.3390\/pharmaceutics13091493","journal-title":"Pharmaceutics"},{"issue":"1","key":"3697_CR93","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12943-018-0927-5","volume":"18","author":"D Thomas","year":"2019","unstructured":"Thomas D, Radhakrishnan P. Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. Mol Cancer. 2019;18(1):14.","journal-title":"Mol Cancer"},{"issue":"8","key":"3697_CR94","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.apsb.2019.11.013","volume":"10","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Zhou W, Chen X, Wang Q, Li C, Chen Q, et al. Bone marrow mesenchymal stem cells-derived exosomes for penetrating and targeted chemotherapy of pancreatic cancer. Acta Pharm Sin B. 2020;10(8):1563\u201375.","journal-title":"Acta Pharm Sin B"},{"key":"3697_CR95","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.actbio.2019.10.022","volume":"101","author":"Y-J Li","year":"2020","unstructured":"Li Y-J, Wu J-Y, Wang J-M, Hu X-B, Cai J-X, Xiang D-X. Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancer. Acta Biomater. 2020;101:519\u201330.","journal-title":"Acta Biomater"},{"issue":"12","key":"3697_CR96","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1038\/s41477-024-01869-8","volume":"10","author":"AR Fernie","year":"2024","unstructured":"Fernie AR, Liu F, Zhang Y. Post-genomic illumination of Paclitaxel biosynthesis. Nat Plants. 2024;10(12):1875\u201385.","journal-title":"Nat Plants"},{"issue":"41","key":"3697_CR97","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.2174\/1381612829666221102155212","volume":"28","author":"A Ahmed Khalil","year":"2022","unstructured":"Ahmed Khalil A, Rauf A, Alhumaydhi FA, Aljohani ASM, Javed MS, Khan MA, et al. Recent developments and anticancer therapeutics of paclitaxel: an update. Curr Pharm Des. 2022;28(41):3363\u201373.","journal-title":"Curr Pharm Des"},{"issue":"3","key":"3697_CR98","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jconrel.2013.05.041","volume":"170","author":"DA Yardley","year":"2013","unstructured":"Yardley DA. nab-Paclitaxel mechanisms of action and delivery. J Control Release. 2013;170(3):365\u201372.","journal-title":"J Control Release"},{"key":"3697_CR99","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.critrevonc.2019.04.021","volume":"139","author":"X Guo","year":"2019","unstructured":"Guo X, Sun H, Dong J, Feng Y, Li H, Zhuang R, et al. Does nab-paclitaxel have a higher incidence of peripheral neuropathy than solvent-based paclitaxel? Evidence from a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2019;139:16\u201323.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"31","key":"3697_CR100","doi-asserted-by":"publisher","first-page":"6358","DOI":"10.2174\/0929867327666201111143725","volume":"28","author":"M Zhou","year":"2021","unstructured":"Zhou M, Han S, Aras O, An F. Recent advances in Paclitaxel-based Self-Delivery nanomedicine for cancer therapy. Curr Med Chem. 2021;28(31):6358\u201374.","journal-title":"Curr Med Chem"},{"issue":"Pt 1","key":"3697_CR101","doi-asserted-by":"publisher","first-page":"143068","DOI":"10.1016\/j.ijbiomac.2025.143068","volume":"310","author":"S Abbaspour","year":"2025","unstructured":"Abbaspour S, Mohamadzadeh M, Shojaosadati SA. Protein-based nanocarriers for Paclitaxel (PTX) delivery in cancer treatment: a review. Int J Biol Macromol. 2025;310(Pt 1):143068.","journal-title":"Int J Biol Macromol"},{"issue":"2","key":"3697_CR102","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/10408347.2017.1416283","volume":"48","author":"RC Alves","year":"2018","unstructured":"Alves RC, Fernandes RP, Eloy JO, Salgado HRN, Chorilli M. Characteristics, properties and analytical methods of paclitaxel: a review. Crit Rev Anal Chem. 2018;48(2):110\u20138.","journal-title":"Crit Rev Anal Chem"},{"key":"3697_CR103","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jconrel.2014.07.042","volume":"192","author":"L Pascucci","year":"2014","unstructured":"Pascucci L, Cocc\u00e8 V, Bonomi A, Ami D, Ceccarelli P, Ciusani E, et al. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. J Control Release. 2014;192:262\u201370.","journal-title":"J Control Release"},{"key":"3697_CR104","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11020061","author":"V Cocc\u00e8","year":"2019","unstructured":"Cocc\u00e8 V, Franz\u00e8 S, Brini AT, Giann\u00ec AB, Pascucci L, Ciusani E, et al. In vitro anticancer activity of extracellular vesicles (EVs) secreted by gingival mesenchymal stromal cells primed with Paclitaxel. Pharmaceutics. 2019;11(2):61. https:\/\/doi.org\/10.3390\/pharmaceutics11020061","journal-title":"Pharmaceutics"},{"key":"3697_CR105","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jconrel.2022.05.012","volume":"347","author":"H Al Faruque","year":"2022","unstructured":"Al Faruque H, Choi E-S, Kim J-H, Kim E. Enhanced effect of autologous EVs delivering Paclitaxel in pancreatic cancer. J Control Release. 2022;347:330\u201346.","journal-title":"J Control Release"},{"key":"3697_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104542","volume":"151","author":"J Benjanuwattra","year":"2020","unstructured":"Benjanuwattra J, Siri-Angkul N, Chattipakorn SC, Chattipakorn N. Doxorubicin and its proarrhythmic effects: a comprehensive review of the evidence from experimental and clinical studies. Pharmacol Res. 2020;151:104542.","journal-title":"Pharmacol Res"},{"key":"3697_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119527","volume":"278","author":"S Sritharan","year":"2021","unstructured":"Sritharan S, Sivalingam N. A comprehensive review on time-tested anticancer drug doxorubicin. Life Sci. 2021;278:119527.","journal-title":"Life Sci"},{"key":"3697_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2023.101205","volume":"93","author":"R Mattioli","year":"2023","unstructured":"Mattioli R, Ilari A, Colotti B, Mosca L, Fazi F, Colotti G. Doxorubicin and other anthracyclines in cancers: activity, chemoresistance and its overcoming. Mol Aspects Med. 2023;93:101205.","journal-title":"Mol Aspects Med"},{"issue":"1","key":"3697_CR109","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12951-019-0526-7","volume":"17","author":"C Gong","year":"2019","unstructured":"Gong C, Tian J, Wang Z, Gao Y, Wu X, Ding X, et al. Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified MicroRNA 159 for triple-negative breast cancer therapy. J Nanobiotechnol. 2019;17(1):93.","journal-title":"J Nanobiotechnol"},{"key":"3697_CR110","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2147\/IJN.S191313","volume":"14","author":"R Kanchanapally","year":"2019","unstructured":"Kanchanapally R, Deshmukh SK, Chavva SR, Tyagi N, Srivastava SK, Patel GK, et al. Drug-loaded Exosomal preparations from different cell types exhibit distinctive loading capability, yield, and antitumor efficacies: a comparative analysis. Int J Nanomed. 2019;14:531\u201341.","journal-title":"Int J Nanomed"},{"key":"3697_CR111","doi-asserted-by":"publisher","first-page":"121056","DOI":"10.1016\/j.biomaterials.2021.121056","volume":"276","author":"J Wang","year":"2021","unstructured":"Wang J, Chen P, Dong Y, Xie H, Wang Y, Soto F, et al. Designer exosomes enabling tumor targeted efficient chemo\/gene\/photothermal therapy. Biomaterials. 2021;276:121056.","journal-title":"Biomaterials"},{"key":"3697_CR112","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223\u201349.","journal-title":"Annu Rev Pathol"},{"issue":"3","key":"3697_CR113","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1080\/08923973.2022.2145966","volume":"45","author":"J Yu","year":"2023","unstructured":"Yu J, Yin Y, Yu Y, Cheng M, Zhang S, Jiang S, et al. Effect of concomitant antibiotics use on patient outcomes and adverse effects in patients treated with ICIs. Immunopharmacol Immunotoxicol. 2023;45(3):386\u201394.","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"1","key":"3697_CR114","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12885-023-10811-8","volume":"23","author":"SJ Park","year":"2023","unstructured":"Park SJ, Park JY, Shin K, Hong TH, Lee M, Kim Y, et al. Clinical significance of serum-derived exosomal PD-L1 expression in patients with advanced pancreatic cancer. BMC Cancer. 2023;23(1):389.","journal-title":"BMC Cancer"},{"key":"3697_CR115","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133305","author":"A Lux","year":"2019","unstructured":"Lux A, Kahlert C, Gr\u00fctzmann R, Pilarsky C. C-Met and PD-L1 on circulating exosomes as diagnostic and prognostic markers for pancreatic cancer. Int J Mol Sci. 2019;20(13):3305. https:\/\/doi.org\/10.3390\/ijms20133305","journal-title":"Int J Mol Sci"},{"issue":"8","key":"3697_CR116","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41422-018-0060-4","volume":"28","author":"Y Yang","year":"2018","unstructured":"Yang Y, Li C-W, Chan L-C, Wei Y, Hsu J-M, Xia W, et al. Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell Res. 2018;28(8):862\u20134.","journal-title":"Cell Res"},{"key":"3697_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1395332","volume":"15","author":"M-M Lu","year":"2024","unstructured":"Lu M-M, Yang Y. Exosomal. PD-L1 in cancer and other fields: recent advances and perspectives. Front Immunol. 2024;15:1395332.","journal-title":"Front Immunol"},{"issue":"3","key":"3697_CR118","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.1097\/MPA.0000000000002419","volume":"54","author":"YC Yoon","year":"2025","unstructured":"Yoon YC, Lee D, Park JH, Kim O-H, Choi HJ, Kim S-J. Enhancing pancreatic cancer therapy with targeted CD133-exosome delivery of PD-L1 sirna: a preclinical investigation. Pancreas. 2025;54(3):e210-20.","journal-title":"Pancreas"},{"key":"3697_CR119","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020336","author":"J Xiang","year":"2024","unstructured":"Xiang J, Zheng B, Zhao L, He Y, Lou F, Li R, et al. Exo70 promotes the invasion of pancreatic cancer cells via the regulation of exosomes. Cancers. 2024;16(2):336. https:\/\/doi.org\/10.3390\/cancers16020336","journal-title":"Cancers"},{"issue":"6","key":"3697_CR120","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","volume":"24","author":"LH Butterfield","year":"2024","unstructured":"Butterfield LH, Najjar YG. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat Rev Immunol. 2024;24(6):399\u2013416.","journal-title":"Nat Rev Immunol"},{"key":"3697_CR121","doi-asserted-by":"publisher","DOI":"10.1101\/2025.03.03.25322827","author":"VS LeBleu","year":"2025","unstructured":"LeBleu VS, Smaglo BG, Mahadevan KK, Kirtley ML, McAndrews KM, Mendt M, et al. KRAS G12D -specific targeting with engineered exosomes reprograms the immune microenvironment to enable efficacy of immune checkpoint therapy in PDAC patients. medRxiv. 2025. https:\/\/doi.org\/10.1101\/2025.03.03.25322827.","journal-title":"medRxiv"},{"key":"3697_CR122","doi-asserted-by":"publisher","first-page":"120546","DOI":"10.1016\/j.biomaterials.2020.120546","volume":"268","author":"W Zhou","year":"2021","unstructured":"Zhou W, Zhou Y, Chen X, Ning T, Chen H, Guo Q, et al. Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. Biomaterials. 2021;268:120546.","journal-title":"Biomaterials"},{"issue":"24","key":"3697_CR123","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1182\/blood-2017-11-785873","volume":"131","author":"D Avigan","year":"2018","unstructured":"Avigan D, Rosenblatt J. Vaccine therapy in hematologic malignancies. Blood. 2018;131(24):2640\u201350.","journal-title":"Blood"},{"issue":"5","key":"3697_CR124","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nrc2373","volume":"8","author":"CJM Melief","year":"2008","unstructured":"Melief CJM, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer. 2008;8(5):351\u201360.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3697_CR125","first-page":"53","volume":"9","author":"X Huang","year":"2022","unstructured":"Huang X, Zhang G, Tang T-Y, Gao X, Liang T-B. Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine. Mil Med Res. 2022;9(1):53.","journal-title":"Mil Med Res"},{"key":"3697_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2022.106993","volume":"108","author":"R Dhar","year":"2022","unstructured":"Dhar R, Bhattacharya B, Mandal D, Devi A, Thorat ND. Exosome-based cancer vaccine: a cutting-edge approach - correspondence. Int J Surg. 2022;108:106993.","journal-title":"Int J Surg"},{"issue":"28","key":"3697_CR127","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.2217\/fon-2017-0343","volume":"13","author":"TL Whiteside","year":"2017","unstructured":"Whiteside TL. The effect of tumor-derived exosomes on immune regulation and cancer immunotherapy. Future Oncol (London England). 2017;13(28):2583\u201392.","journal-title":"Future Oncol (London England)"},{"issue":"8","key":"3697_CR128","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1016\/j.apsb.2021.04.012","volume":"11","author":"H Chen","year":"2021","unstructured":"Chen H, Chengalvala V, Hu H, Sun D. Tumor-derived exosomes: nanovesicles made by cancer cells to promote cancer metastasis. Acta Pharm Sin B. 2021;11(8):2136\u201349.","journal-title":"Acta Pharm Sin B"},{"key":"3697_CR129","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/bs.acc.2015.12.005","volume":"74","author":"TL Whiteside","year":"2016","unstructured":"Whiteside TL. Tumor-derived exosomes and their role in cancer progression. Adv Clin Chem. 2016;74:103\u201341.","journal-title":"Adv Clin Chem"},{"issue":"4","key":"3697_CR130","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3390\/vaccines3041019","volume":"3","author":"KE Kunigelis","year":"2015","unstructured":"Kunigelis KE, Graner MW. The dichotomy of tumor exosomes (TEX) in cancer immunity: is it all in the context?? Vaccines. 2015;3(4):1019\u201351.","journal-title":"Vaccines"},{"issue":"9","key":"3697_CR131","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1080\/21645515.2016.1179844","volume":"12","author":"JD Elster","year":"2016","unstructured":"Elster JD, Krishnadas DK, Lucas KG. Dendritic cell vaccines: a review of recent developments and their potential pediatric application. Hum Vaccin Immunother. 2016;12(9):2232\u20139.","journal-title":"Hum Vaccin Immunother"},{"key":"3697_CR132","doi-asserted-by":"publisher","first-page":"121306","DOI":"10.1016\/j.biomaterials.2021.121306","volume":"280","author":"W Zhou","year":"2022","unstructured":"Zhou W, Chen X, Zhou Y, Shi S, Liang C, Yu X, et al. Exosomes derived from immunogenically dying tumor cells as a versatile tool for vaccination against pancreatic cancer. Biomaterials. 2022;280:121306.","journal-title":"Biomaterials"},{"key":"3697_CR133","doi-asserted-by":"publisher","unstructured":"Verdi J, Ketabchi N, Noorbakhsh N, Saleh M, Ebrahimi-Barough S, Seyhoun I, et al. Development and clinical application of tumor-derived exosomes in patients with cancer. Curr Stem Cell Res Ther. 2022;17(1):91-102. https:\/\/doi.org\/10.2174\/1574888X16666210622123942","DOI":"10.2174\/1574888X16666210622123942"},{"issue":"6","key":"3697_CR134","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","volume":"38","author":"AS Bear","year":"2020","unstructured":"Bear AS, Vonderheide RH, O\u2019Hara MH. Challenges and opportunities for pancreatic cancer immunotherapy. Cancer Cell. 2020;38(6):788\u2013802.","journal-title":"Cancer Cell"},{"issue":"1","key":"3697_CR135","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/jso.24627","volume":"116","author":"CJ DeSelm","year":"2017","unstructured":"DeSelm CJ, Tano ZE, Varghese AM, Adusumilli PS. CAR T-cell therapy for pancreatic cancer. J Surg Oncol. 2017;116(1):63\u201374.","journal-title":"J Surg Oncol"},{"key":"3697_CR136","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.2147\/IJN.S445101","volume":"19","author":"D Hu","year":"2024","unstructured":"Hu D, Yang R, Wang G, Li H, Fan X, Liang G. Emerging strategies to overcome current CAR-T therapy dilemmas - exosomes derived from CAR-T cells. Int J Nanomed. 2024;19:2773\u201391.","journal-title":"Int J Nanomed"},{"issue":"2","key":"3697_CR137","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1080\/25785826.2020.1818482","volume":"44","author":"A Dutta","year":"2021","unstructured":"Dutta A. Exosomes-based cell-free cancer therapy: a novel strategy for targeted therapy. Immunol Med. 2021;44(2):116\u201323.","journal-title":"Immunol Med"},{"key":"3697_CR138","doi-asserted-by":"publisher","first-page":"1386856","DOI":"10.3389\/fimmu.2024.1386856","volume":"15","author":"B Mart\u00edn-Antonio","year":"2024","unstructured":"Mart\u00edn-Antonio B, Blanco B, Gonz\u00e1lez-Murillo \u00c1, Hidalgo L, Minguill\u00f3n J, P\u00e9rez-Chac\u00f3n G. Newer generations of multi-target CAR and STAb-T immunotherapeutics: NEXT cart consortium as a cooperative effort to overcome current limitations. Front Immunol. 2024;15:1386856.","journal-title":"Front Immunol"},{"issue":"1","key":"3697_CR139","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-020-00890-6","volume":"13","author":"Y Tian","year":"2020","unstructured":"Tian Y, Li Y, Shao Y, Zhang Y. Gene modification strategies for next-generation CAR T cells against solid cancers. J Hematol Oncol. 2020;13(1):54.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3697_CR140","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1038\/s41467-019-12321-3","volume":"10","author":"W Fu","year":"2019","unstructured":"Fu W, Lei C, Liu S, Cui Y, Wang C, Qian K, et al. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. Nat Commun. 2019;10(1):4355.","journal-title":"Nat Commun"},{"issue":"1","key":"3697_CR141","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13287-024-03783-4","volume":"15","author":"F Sani","year":"2024","unstructured":"Sani F, Shojaei S, Tabatabaei SA, Khorraminejad-Shirazi M, Latifi M, Sani M, et al. CAR-T cell-derived exosomes: a new perspective for cancer therapy. Stem Cell Res Ther. 2024;15(1):174.","journal-title":"Stem Cell Res Ther"},{"issue":"5","key":"3697_CR142","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1631\/jzus.B1500305","volume":"17","author":"R-S Que","year":"2016","unstructured":"Que R-S, Lin C, Ding G-P, Wu Z-R, Cao L-P. Increasing the immune activity of exosomes: the effect of miRNA-depleted exosome proteins on activating dendritic cell\/cytokine-induced killer cells against pancreatic cancer. J Zhejiang Univ Sci B. 2016;17(5):352\u201360.","journal-title":"J Zhejiang Univ Sci B"},{"issue":"6","key":"3697_CR143","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.trecan.2018.04.001","volume":"4","author":"AH Morrison","year":"2018","unstructured":"Morrison AH, Byrne KT, Vonderheide RH. Immunotherapy and prevention of pancreatic cancer. Trends Cancer. 2018;4(6):418\u201328.","journal-title":"Trends Cancer"},{"issue":"6","key":"3697_CR144","doi-asserted-by":"publisher","first-page":"e1319044","DOI":"10.1080\/2162402X.2017.1319044","volume":"6","author":"L Xiao","year":"2017","unstructured":"Xiao L, Erb U, Zhao K, Hackert T, Z\u00f6ller M. Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer. Oncoimmunology. 2017;6(6):e1319044.","journal-title":"Oncoimmunology"},{"key":"3697_CR145","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jconrel.2020.12.039","volume":"330","author":"Y Jang","year":"2021","unstructured":"Jang Y, Kim H, Yoon S, Lee H, Hwang J, Jung J, et al. Exosome-based photoacoustic imaging guided photodynamic and immunotherapy for the treatment of pancreatic cancer. J Control Release. 2021;330:293\u2013304.","journal-title":"J Control Release"},{"issue":"37","key":"3697_CR146","doi-asserted-by":"publisher","first-page":"13343","DOI":"10.3748\/wjg.v20.i37.13343","volume":"20","author":"S-X Liu","year":"2014","unstructured":"Liu S-X, Xia Z-S, Zhong Y-Q. Gene therapy in pancreatic cancer. World J Gastroenterol. 2014;20(37):13343\u201368.","journal-title":"World J Gastroenterol"},{"key":"3697_CR147","doi-asserted-by":"publisher","first-page":"120369","DOI":"10.1016\/j.biomaterials.2020.120369","volume":"264","author":"L Xu","year":"2021","unstructured":"Xu L, Faruqu FN, Lim YM, Lim KY, Liam-Or R, Walters AA, et al. Exosome-mediated RNAi of PAK4 prolongs survival of pancreatic cancer mouse model after loco-regional treatment. Biomaterials. 2021;264:120369.","journal-title":"Biomaterials"},{"issue":"1","key":"3697_CR148","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.1038\/s41467-018-07339-y","volume":"9","author":"D Novo","year":"2018","unstructured":"Novo D, Heath N, Mitchell L, Caligiuri G, MacFarlane A, Reijmer D, et al. Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels. Nat Commun. 2018;9(1):5069.","journal-title":"Nat Commun"},{"issue":"1","key":"3697_CR149","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00262-024-03849-5","volume":"74","author":"T Ohtani","year":"2024","unstructured":"Ohtani T, Kuroda S, Kanaya N, Kakiuchi Y, Kumon K, Hashimoto M, et al. Dendritic cell maturation is induced by p53-armed oncolytic adenovirus via tumor-derived exosomes enhancing systemic antitumor immunity. Cancer Immunol Immunother. 2024;74(1):12.","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"3697_CR150","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/jclinpath-2018-205095","volume":"71","author":"AJ McCarthy","year":"2018","unstructured":"McCarthy AJ, Chetty R. Smad4\/DPC4. J Clin Pathol. 2018;71(8):661\u20134.","journal-title":"J Clin Pathol"},{"issue":"22","key":"3697_CR151","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1200\/JCO.2010.33.8038","volume":"29","author":"CH Crane","year":"2011","unstructured":"Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol. 2011;29(22):3037\u201343.","journal-title":"J Clin Oncol"},{"key":"3697_CR152","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1476-4598-2-12","volume":"2","author":"JP Duffy","year":"2003","unstructured":"Duffy JP, Eibl G, Reber HA, Hines OJ. Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer. 2003;2:12.","journal-title":"Mol Cancer"},{"key":"3697_CR153","doi-asserted-by":"publisher","first-page":"4769385","DOI":"10.1155\/2022\/4769385","volume":"2022","author":"L Wang","year":"2022","unstructured":"Wang L, Yang L, Zhuang T, Shi X. Tumor-Derived Exosomal miR-29b reduces angiogenesis in pancreatic cancer by Silencing ROBO1 and SRGAP2. J Immunol Res. 2022;2022:4769385.","journal-title":"J Immunol Res"},{"issue":"3","key":"3697_CR154","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.7150\/ijbs.67675","volume":"18","author":"K Chen","year":"2022","unstructured":"Chen K, Wang Q, Liu X, Wang F, Yang Y, Tian X. Hypoxic pancreatic cancer derived exosomal miR-30b-5p promotes tumor angiogenesis by inhibiting GJA1 expression. Int J Biol Sci. 2022;18(3):1220\u201337.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"3697_CR155","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12943-018-0867-0","volume":"17","author":"V de Araujo Farias","year":"2018","unstructured":"de Araujo Farias V, O\u2019Valle F, Serrano-Saenz S, Anderson P, Andr\u00e9s E, L\u00f3pez-Pe\u00f1alver J, et al. Exosomes derived from mesenchymal stem cells enhance radiotherapy-induced cell death in tumor and metastatic tumor foci. Mol Cancer. 2018;17(1):122.","journal-title":"Mol Cancer"},{"key":"3697_CR156","doi-asserted-by":"publisher","first-page":"1299384","DOI":"10.3389\/fonc.2023.1299384","volume":"13","author":"Y Song","year":"2023","unstructured":"Song Y, Song Q, Hu D, Sun B, Gao M, Liang X, et al. The potential applications of artificially modified exosomes derived from mesenchymal stem cells in tumor therapy. Front Oncol. 2023;13:1299384.","journal-title":"Front Oncol"},{"issue":"1\u20132","key":"3697_CR157","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ijpharm.2018.07.067","volume":"549","author":"FH Shamili","year":"2018","unstructured":"Shamili FH, Bayegi HR, Salmasi Z, Sadri K, Mahmoudi M, Kalantari M, et al. Exosomes derived from TRAIL-engineered mesenchymal stem cells with effective anti-tumor activity in a mouse melanoma model. Int J Pharm. 2018;549(1\u20132):218\u201329.","journal-title":"Int J Pharm"},{"issue":"2","key":"3697_CR158","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/sj.cgt.7700773","volume":"12","author":"D Jacob","year":"2005","unstructured":"Jacob D, Davis JJ, Zhang L, Zhu H, Teraishi F, Fang B. Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter. Cancer Gene Ther. 2005;12(2):109\u201315.","journal-title":"Cancer Gene Ther"},{"issue":"9","key":"3697_CR159","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/cgt.2012.46","volume":"19","author":"MR Moniri","year":"2012","unstructured":"Moniri MR, Sun XY, Rayat J, Dai D, Ao Z, He Z, et al. TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells. Cancer Gene Ther. 2012;19(9):652\u20138.","journal-title":"Cancer Gene Ther"},{"key":"3697_CR160","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23147810","author":"E Rimmer","year":"2022","unstructured":"Rimmer E, Rashid S, Kraev I, Miralles F, Elia A. Extracellular vesicles inhibit the response of pancreatic ductal adenocarcinoma cells to gemcitabine and TRAIL treatment. Int J Mol Sci. 2022;23(14):7810. https:\/\/doi.org\/10.3390\/ijms23147810","journal-title":"Int J Mol Sci"},{"key":"3697_CR161","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcp.2023.101894","volume":"67","author":"D Klimova","year":"2023","unstructured":"Klimova D, Jakubechova J, Altanerova U, Nicodemou A, Styk J, Szemes T, et al. Extracellular vesicles derived from dental mesenchymal stem\/stromal cells with gemcitabine as a cargo have an inhibitory effect on the growth of pancreatic carcinoma cell lines in vitro. Mol Cell Probes. 2023;67:101894.","journal-title":"Mol Cell Probes"},{"key":"3697_CR162","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.07.002","author":"KK Mahadevan","year":"2023","unstructured":"Mahadevan KK, McAndrews KM, LeBleu VS, Yang S, Lyu H, Li B, et al. KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8\u2009+\u2009T cells. Cancer Cell. 2023;41(9):1606-1620.e8. https:\/\/doi.org\/10.1016\/j.ccell.2023.07.002","journal-title":"Cancer Cell"},{"issue":"7659","key":"3697_CR163","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature22341","volume":"546","author":"S Kamerkar","year":"2017","unstructured":"Kamerkar S, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA, et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 2017;546(7659):498\u2013503.","journal-title":"Nature"},{"key":"3697_CR164","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18061231","author":"M Rouanet","year":"2017","unstructured":"Rouanet M, Lebrin M, Gross F, Bournet B, Cordelier P, Buscail L. Gene therapy for pancreatic cancer: specificity, issues and hopes. Int J Mol Sci. 2017;18(6):1231. https:\/\/doi.org\/10.3390\/ijms18061231","journal-title":"Int J Mol Sci"},{"issue":"8","key":"3697_CR165","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","volume":"20","author":"M Winkle","year":"2021","unstructured":"Winkle M, El-Daly SM, Fabbri M, Calin GA. Noncoding RNA therapeutics - challenges and potential solutions. Nat Rev Drug Discov. 2021;20(8):629\u201351.","journal-title":"Nat Rev Drug Discov"},{"key":"3697_CR166","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.canlet.2018.10.039","volume":"442","author":"Y Ding","year":"2019","unstructured":"Ding Y, Cao F, Sun H, Wang Y, Liu S, Wu Y, et al. Exosomes derived from human umbilical cord mesenchymal stromal cells deliver exogenous miR-145-5p to inhibit pancreatic ductal adenocarcinoma progression. Cancer Lett. 2019;442:351\u201361.","journal-title":"Cancer Lett"},{"issue":"5","key":"3697_CR167","doi-asserted-by":"publisher","first-page":"5764","DOI":"10.18632\/oncotarget.23532","volume":"9","author":"S Han","year":"2018","unstructured":"Han S, Gonzalo DH, Feely M, Rinaldi C, Belsare S, Zhai H, et al. Stroma-derived extracellular vesicles deliver tumor-suppressive miRNAs to pancreatic cancer cells. Oncotarget. 2018;9(5):5764\u201377.","journal-title":"Oncotarget"},{"key":"3697_CR168","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.2147\/DDDT.S265423","volume":"14","author":"L Zuo","year":"2020","unstructured":"Zuo L, Tao H, Xu H, Li C, Qiao G, Guo M, et al. Exosomes-Coated miR-34a displays potent antitumor activity in pancreatic cancer both in vitro and in vivo. Drug Des Devel Ther. 2020;14:3495\u2013507.","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"3697_CR169","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/s41417-024-00771-x","volume":"31","author":"V De Castro","year":"2024","unstructured":"De Castro V, Galaine J, Loyon R, Godet Y. CRISPR-cas gene knockouts to optimize engineered T cells for cancer immunotherapy. Cancer Gene Ther. 2024;31(8):1124\u201334.","journal-title":"Cancer Gene Ther"},{"key":"3697_CR170","first-page":"448","volume":"17","author":"D Gulei","year":"2019","unstructured":"Gulei D, Berindan-Neagoe I. Activation of necroptosis by engineered self tumor-derived exosomes loaded with CRISPR\/Cas9. Mol Ther. 2019;17:448\u201351.","journal-title":"Mol Ther"},{"key":"3697_CR171","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202000875","author":"KM McAndrews","year":"2021","unstructured":"McAndrews KM, Xiao F, Chronopoulos A, LeBleu VS, Kugeratski FG, Kalluri R. Exosome-mediated delivery of CRISPR\/Cas9 for targeting of oncogenic KrasG12D in pancreatic cancer. Life Sci Alliance. 2021;4(9):e202000875. https:\/\/doi.org\/10.26508\/lsa.202000875","journal-title":"Life Sci Alliance"},{"issue":"3\u20134","key":"3697_CR172","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1089\/hum.2022.210","volume":"34","author":"L Quillien","year":"2023","unstructured":"Quillien L, Buscail L, Cordelier P. Pancreatic cancer cell and gene biotherapies: past, present, and future. Hum Gene Ther. 2023;34(3\u20134):150\u201361.","journal-title":"Hum Gene Ther"},{"issue":"4","key":"3697_CR173","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1517\/14712598.2015.1001734","volume":"15","author":"HM Singh","year":"2015","unstructured":"Singh HM, Ungerechts G, Tsimberidou AM. Gene and cell therapy for pancreatic cancer. Expert Opin Biol Ther. 2015;15(4):505\u201316.","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"3697_CR174","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1039\/C4CS00370E","volume":"44","author":"L Wu","year":"2015","unstructured":"Wu L, Qu X. Cancer biomarker detection: recent achievements and challenges. Chem Soc Rev. 2015;44(10):2963\u201397.","journal-title":"Chem Soc Rev"},{"key":"3697_CR175","doi-asserted-by":"publisher","first-page":"8019","DOI":"10.2147\/IJN.S272378","volume":"15","author":"VC Kok","year":"2020","unstructured":"Kok VC, Yu C-C. Cancer-derived exosomes: their role in cancer biology and biomarker development. Int J Nanomed. 2020;15:8019\u201336.","journal-title":"Int J Nanomed"},{"issue":"47","key":"3697_CR176","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk1098","volume":"9","author":"S Hyung","year":"2023","unstructured":"Hyung S, Ko J, Heo YJ, Blum SM, Kim ST, Park SH, et al. Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer. Sci Adv. 2023;9(47):eadk1098.","journal-title":"Sci Adv"},{"key":"3697_CR177","doi-asserted-by":"publisher","first-page":"1093607","DOI":"10.3389\/fimmu.2022.1093607","volume":"13","author":"H Zhang","year":"2022","unstructured":"Zhang H, Wang S, Sun M, Cui Y, Xing J, Teng L, et al. Exosomes as smart drug delivery vehicles for cancer immunotherapy. Front Immunol. 2022;13:1093607.","journal-title":"Front Immunol"},{"issue":"5","key":"3697_CR178","first-page":"2226","volume":"12","author":"J Cheng","year":"2022","unstructured":"Cheng J, Wang X, Yuan X, Liu G, Chu Q. Emerging roles of exosome-derived biomarkers in cancer theranostics: messages from novel protein targets. Am J Cancer Res. 2022;12(5):2226\u201348.","journal-title":"Am J Cancer Res"},{"issue":"7","key":"3697_CR179","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s12094-023-03106-8","volume":"25","author":"X Liu","year":"2023","unstructured":"Liu X, Li N. New thoughts and findings on invasion and metastasis of pancreatic ductal adenocarcinoma (PDAC) from comparative proteomics: multi-target therapy. Clin Transl Oncol. 2023;25(7):1991\u20138.","journal-title":"Clin Transl Oncol"},{"issue":"21","key":"3697_CR180","doi-asserted-by":"publisher","first-page":"5986","DOI":"10.7150\/thno.26650","volume":"8","author":"J Fan","year":"2018","unstructured":"Fan J, Wei Q, Koay EJ, Liu Y, Ning B, Bernard PW, et al. Chemoresistance transmission via exosome-mediated EphA2 transfer in pancreatic cancer. Theranostics. 2018;8(21):5986\u201394.","journal-title":"Theranostics"},{"issue":"7","key":"3697_CR181","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1172\/JCI84658","volume":"126","author":"H Kimura","year":"2016","unstructured":"Kimura H, Fumoto K, Shojima K, Nojima S, Osugi Y, Tomihara H, et al. CKAP4 is a Dickkopf1 receptor and is involved in tumor progression. J Clin Invest. 2016;126(7):2689\u2013705.","journal-title":"J Clin Invest"},{"key":"3697_CR182","doi-asserted-by":"publisher","DOI":"10.3390\/biom11101469","author":"K Schlick","year":"2021","unstructured":"Schlick K, Kiem D, Greil R. Recent advances in pancreatic cancer: novel prognostic biomarkers and targeted therapy-a review of the literature. Biomolecules. 2021;11(10):1469. https:\/\/doi.org\/10.3390\/biom11101469","journal-title":"Biomolecules"},{"issue":"17","key":"3697_CR183","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.297.17.1901","volume":"297","author":"M Bloomston","year":"2007","unstructured":"Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, et al. Microrna expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007;297(17):1901\u20138.","journal-title":"JAMA"},{"issue":"1","key":"3697_CR184","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13062-023-00356-y","volume":"18","author":"K Zhang","year":"2023","unstructured":"Zhang K, Li Y-J, Peng L-J, Gao H-F, Liu L-M, Chen H. M2 macrophage-derived exosomal miR-193b-3p promotes progression and glutamine uptake of pancreatic cancer by targeting TRIM62. Biol Direct. 2023;18(1):1.","journal-title":"Biol Direct"},{"key":"3697_CR185","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242417523","author":"A Pal","year":"2023","unstructured":"Pal A, Ojha A, Ju J. Functional and potential therapeutic implication of micrornas in pancreatic cancer. Int J Mol Sci. 2023;24(24):17523. https:\/\/doi.org\/10.3390\/ijms242417523","journal-title":"Int J Mol Sci"},{"key":"3697_CR186","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111407","volume":"127","author":"Y Guo","year":"2024","unstructured":"Guo Y, Cui J, Liang X, Chen T, Lu C, Peng T. Pancreatic cancer stem cell-derived exosomal miR-210 mediates macrophage M2 polarization and promotes gemcitabine resistance by targeting FGFRL1. Int Immunopharmacol. 2024;127:111407.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"3697_CR187","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2019.111543","volume":"383","author":"Y Fang","year":"2019","unstructured":"Fang Y, Zhou W, Rong Y, Kuang T, Xu X, Wu W, et al. Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer. Exp Cell Res. 2019;383(1):111543.","journal-title":"Exp Cell Res"},{"issue":"18","key":"3697_CR188","doi-asserted-by":"publisher","first-page":"5287","DOI":"10.1158\/0008-5472.CAN-18-0124","volume":"78","author":"Y Binenbaum","year":"2018","unstructured":"Binenbaum Y, Fridman E, Yaari Z, Milman N, Schroeder A, Ben David G, et al. Transfer of miRNA in macrophage-derived exosomes induces drug resistance in pancreatic adenocarcinoma. Cancer Res. 2018;78(18):5287\u201399.","journal-title":"Cancer Res"},{"key":"3697_CR189","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073914","author":"R Madadjim","year":"2024","unstructured":"Madadjim R, An T, Cui J. Micrornas in pancreatic cancer: advances in biomarker discovery and therapeutic implications. Int J Mol Sci. 2024;25(7):3914. https:\/\/doi.org\/10.3390\/ijms25073914","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3697_CR190","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.xphs.2016.07.022","volume":"106","author":"A Matsumoto","year":"2017","unstructured":"Matsumoto A, Takahashi Y, Nishikawa M, Sano K, Morishita M, Charoenviriyakul C, et al. Role of phosphatidylserine-derived negative surface charges in the recognition and uptake of intravenously injected B16BL6-derived exosomes by macrophages. J Pharm Sci. 2017;106(1):168\u201375.","journal-title":"J Pharm Sci"},{"key":"3697_CR191","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jconrel.2022.05.027","volume":"347","author":"I Kimiz-Gebologlu","year":"2022","unstructured":"Kimiz-Gebologlu I, Oncel SS. Exosomes. Large-scale production, isolation, drug loading efficiency, and biodistribution and uptake. J Control Release. 2022;347:533\u201343.","journal-title":"J Control Release"},{"issue":"1","key":"3697_CR192","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12951-023-02259-6","volume":"22","author":"Z Chen","year":"2024","unstructured":"Chen Z, Xiong M, Tian J, Song D, Duan S, Zhang L. Encapsulation and assessment of therapeutic cargo in engineered exosomes: a systematic review. J Nanobiotechnol. 2024;22(1):18.","journal-title":"J Nanobiotechnol"},{"issue":"8","key":"3697_CR193","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s11095-024-03757-4","volume":"41","author":"Y Takakura","year":"2024","unstructured":"Takakura Y, Hanayama R, Akiyoshi K, Futaki S, Hida K, Ichiki T, et al. Quality and safety considerations for therapeutic products based on extracellular vesicles. Pharm Res. 2024;41(8):1573\u201394.","journal-title":"Pharm Res"},{"issue":"7","key":"3697_CR194","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12458","volume":"13","author":"M Van Delen","year":"2024","unstructured":"Van Delen M, Derdelinckx J, Wouters K, Nelissen I, Cools N. A systematic review and meta-analysis of clinical trials assessing safety and efficacy of human extracellular vesicle-based therapy. J Extracell Vesicles. 2024;13(7):e12458.","journal-title":"J Extracell Vesicles"},{"key":"3697_CR195","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2024.100278","volume":"6","author":"A Thakur","year":"2024","unstructured":"Thakur A, Rai D. Global requirements for manufacturing and validation of clinical grade extracellular vesicles. The Journal of Liquid Biopsy. 2024;6:100278.","journal-title":"The Journal of Liquid Biopsy"},{"key":"3697_CR196","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16060709","author":"A Sharma","year":"2024","unstructured":"Sharma A, Yadav A, Nandy A, Ghatak S. Insight into the functional dynamics and challenges of exosomes in pharmaceutical innovation and precision medicine. Pharmaceutics. 2024;16(6):709. https:\/\/doi.org\/10.3390\/pharmaceutics16060709","journal-title":"Pharmaceutics"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03697-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-025-03697-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03697-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:05:05Z","timestamp":1759158305000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-025-03697-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":196,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3697"],"URL":"https:\/\/doi.org\/10.1186\/s12951-025-03697-0","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"619"}}